Diagnostic imaging of dopamine receptors in pituitary adenomas

European Journal of Endocrinology, Supplement

Volumn 156, Issue 1, 2007, Pages

  De Herder, Wouter W ^a   Reijs, Ambroos E M ^a   Feelders, Richard A ^a   Van Aken, Maarten O ^a   Krenning, Eric P ^a   Van Der Lely, Aart Jan ^a   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CARBON 11; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; EPIDEPRIDE; IODINE 123; METHYLSPIPERONE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; OCTREOTIDE; QUINAGOLIDE; RACLOPRIDE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ACROMEGALY; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS ADENOMA; NONFUNCTIONING PITUITARY ADENOMA; POSITRON EMISSION TOMOGRAPHY; PROLACTINOMA; SCINTIGRAPHY; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROTROPIN SECRETING ADENOMA; TUMOR REGRESSION;

ADENOMA; BENZAMIDES; DOPAMINE ANTAGONISTS; HUMANS; PITUITARY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34249091998     PISSN: 08044635     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02349     Document Type: Conference Paper

References (31)

1. de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SWJ, van der Lely AJ & Krenning EP. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 2006 9 243-248.
2. Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L & Lombardi G. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 2004 89 1674-1683.
3. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ & Lamberts SW. Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2004 89 2452-2462.
4. Spada A, Nicosia S, Cortelazzi L, Pezzo G, Bassetti M, Sartorio A & Giannattasio G. In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide. Journal of Clinical Endocrinology and Metabolism 1983 56 1-10.
5. De Camilli P, Macconi D & Spada A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 1979 278 252-254.
6. Bression D, Brandi AM, Martres MP, Nousbaum A, Cesselin F, Racadot J & Peillon F. Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study. Journal of Clinical Endocrinology and Metabolism 1980 51 1037-1044.
7. Bevan JS, Webster J, Burke CW & Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews 1992 13 220-240.
8. Bevan JS & Burke CW. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clinical Endocrinology 1986 25 561-572.
9. Koga M, Nakao H, Arao M, Sato B, Noma K, Morimoto Y, Kishimoto S, Mori S & Uozumi T. Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinologica 1987 114 595-602.
10. Serri O, Marchisio AM, Collu R, Hardy J & Somma M. Dopaminergic binding sites in human pituitary adenomas other than prolactinomas. Hormone Research 1984 19 97-102.
11. 3H]Spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone. Journal of Clinical Endocrinology and Metabolism 1980 50 387-391.
12. Pirker W, Brucke T, Riedl M, Clodi M, Luger A, Asenbaum S, Podreka I & Deecke L. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors. Journal of Neural Transmission. General Section 1994 97 235-244.
13. Scillitani A, Dicembrino F, Di Fazio P, Vettori PP, D'Angelo V, Scarabino T & Liuzzi A. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (D3ZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. Journal of Clinical Endocrinology and Metabolism 1995 80 2523-2525.
14. 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 248-252.
15. de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland LJ, Nobels FR, Oei HY, Krenning EP & Lamberts SW. In vivo imaging of pituitary tumours using a radiolabeled dopamine D2 receptor radioligand. Clinical Endocrinology 1996 45 755-767.
16. Assies J, Verhoeff NP, Bosch DA & Hofland LJ. Intracranial dissemination of a macroprolactinoma. Clinical Endocrinology 1993 38 539-546.
17. Verhoeff NP, Bemelman FJ, Wiersinga WM & van Royen EA. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma. European Journal of Nuclear Medicine 1993 20 555-561.
18. 123I- methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors. Biomedicine and Pharmacotherapy 1999 53 319-322.
19. Ferone D, Pivonello R, Lastoria S, Faggiano A, del Basso De Caro ML, Cappabianca P, Lombardi G & Colao A. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: Correlation with somatostatin and dopamine D2 receptor scintigraphy. Clinical Endocrinology 2001 54 469-477.
20. Joyce JN, Janowsky A & Neve KA. Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain. Journal of Pharmacology and Experimental Therapeutics 1991 257 1253-1263.
21. 125I]epidepride. Brain Research 1993 609 237-243.
22. Ichise M & Ballinger JR. SPECT imaging of dopamine receptors. Journal of Nuclear Medicine 1996 37 1591-1595.
23. Pirker W, Riedl M, Luger A, Czech T, Rossler K, Asenbaum S, Angelberger P, Kornhuber J, Deecke L, Podreka I & Brucke T. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. Journal of Nuclear Medicine 1996 37 1931-1937.
24. de Herder WW, Reijs AEM, de Swart J, Kaandorp Y, Lamberts SWJ, Krenning EP & Kwekkeboom DJ. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas. European Journal of Nuclear Medicine 1999 26 46-50.
25. Leslie WD, Abrams DN, Greenberg CR & Hobson D. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging. Journal of Nuclear Medicine 1996 37 1589-1591.
26. 123I-epidepride dopamine D2 receptor imaging? European Journal of Endocrinology 2006 155 1-8.
27. 11C-N-methylspiperone. Journal of Computer Assisted Tomography 1986 10 175-180.
28. Muhr C, Bergstrom M, Lundberg PO, Bergstrom K & Langstrom B. In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography. Acta Radiologica. Supplementum 1986 369 406-408.
29. Bergstrom M, Muhr C, Lundberg PO & Langstrom B. PET as a tool in the clinical evaluation of pituitary adenomas. Journal of Nuclear Medicine 1991 32 610-615.
30. Muhr C & Bergstrom M. Positron emission tomography applied in the study of pituitary adenomas. Journal of Endocrinological Investigation 1991 14 509-528.
31. Muhr C, Bergstrom M, Lundberg PO, Hartman M, Bergstrom K, Pellettieri L & Langstrom B. Malignant prolactinoma with multiple intracranial metastases studied with positron emission tomography. Neurosurgery 1988 22 374-379.